Study reveals potential cognitive benefits of antidiabetic drugs

FHS
July 12, 2024
5:05 pm

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer’s disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.

Estetrol by Mithra Pharmaceuticals for Female Sexual Dysfunction: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

April 18, 2024

Single dengue vaccine dose shows mixed results: Protection hinges on prior exposure

Study investigates the protective effects of a single CYD-TDV vaccine dose against dengue virus in Filipino children, revealing that while the vaccine does not protect

March 27, 2024

Greenlane Announces Board’s Approval of Reverse Stock Split Ratio

BOCA RATON, FL / ACCESSWIRE / June 2, 2023 / Greenlane Holdings, Inc. (NASDAQ:GNLN) (“Greenlane”), one of the largest global sellers of premium cannabis accessories,

June 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.